Roche Holding AG (XSWX:ROG)
CHF 251 0 (0%) Market Cap: 201.45 Bil Enterprise Value: 231.01 Bil PE Ratio: 18.96 PB Ratio: 6.91 GF Score: 93/100

Roche Holding AG to Discuss Gazyva in Lupus Nephritis Presented at ASN/ASR 2019 Transcript

Nov 12, 2019 / 03:30PM GMT
Release Date Price: CHF298.1 (+0.05%)
Operator

Ladies and gentlemen, welcome to the Roche live audio webcast on Gazyva in lupus nephritis presented at ASN/ACR 2019 conference call. I am Andre, the Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Karl Mahler, Head of Investor Relations. Please go ahead, sir.

Karl Mahler
Roche Holding AG - Head of IR

Yes, thank you, Andre. Also, a warm welcome from my side to everybody joining us for this Roche audio webcast to discuss the Gazyva Phase II data in lupus nephritis. Actually, we have presented these data over the past 2 weeks at 2 different congresses, at ASN as well as at ACR, the American Society of Nephrology. And I am pleased that we have with us today, Mark Eisner, the Global Head of Product Development, Immunology, Infectious Diseases and Ophthalmology, who will start this call by giving us a short overview on the Roche -- of Roche in immunology. And this will be followed by Larry

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot